Posted by Michael Wonder on 08 Jan 2024
Journey Medical Corporation submits new drug application to FDA for DFD-29 to treat rosacea
5 January 2024 - NDA submission supported by positive Phase 3 clinical data.
Journey Medical Corporation today announced that the Company has submitted a new drug application to the FDA seeking approval for DFD-29 (minocycline hydrochloride 40 mg modified release capsules) for the treatment of inflammatory lesions and erythema of rosacea in adults.
